< BACK iPROLEPSIS presented at the 15th Portuguese Rheumatology Congress Oct 27, 2023 iPROLEPSIS project and iPROLEPSIS-PDPID study presented at the 15th Portuguese Rheumatology Congress On October 27, 2023, the Portuguese Society of Rheumatology (SPR) , a dedicated partner of iPROLEPSIS , took the stage at the 15th Portuguese Rheumatology Congress (XXV Congresso Português de Reumatologia) , the event attended by around 700 individuals, mainly rheumatologists and GPs. Cátia Gonçalves, Reuma.pt Study Coordinator, and Ana M. Rodrigues, Reuma.pt National Coordinator and Assistant Professor at NOVA Medical School, provided a comprehensive overview of the iPROLEPSIS project, its goals, and clinical studies. They also introduced the iPROLEPSIS-PDPID study , focusing on PsA digital phenotyping and inflammation drivers. Portuguese Rheumatology centres were invited to participate in the iPROLEPSIS-PDPID study, marking a significant step in advancing our research. News & Events iPROLEPSIS.png News & Events iPROLEPSIS.png 1/1 PREVIOUS NEXT

< BACK Understanding Enthesitis in Psoriatic Arthritis Oct 7, 2024 iPROLEPSIS presented in the 16th Panhellenic Conference of EPEMY Aristotle University of Thessaloniki presented iPROLEPSIS in the 16th Panhellenic Conference of EPEMY held in Ioannina, Greece, from 3-6 October 2024. The presentation addressed important topics related to nesting, the role of enthesitis in Psoriatic Arthritis and Axial Spondyloarthritis, and the most appropriate treatment approaches for enthesitis and digitalis. This conference focused on inflammatory and autoimmune rheumatic, gastrointestinal, and skin diseases, as well as osteoporosis and osteoarthritis. Individual sessions covered Covid-19, cancer, neurological syndromes, and co-morbidities. The event emphasised clinically applied treatments, with interactive, cross-company tutorials and presentations of research projects from domestic centers, which were awarded for their contributions. Read more about the conference here . 1/1 PREVIOUS NEXT

< BACK Understanding Patient Perspectives on Digital Biomarkers for Psoriatic Arthritis Nov 28, 2024 A new study explores opportunities and challenges in using digital biomarkers for Psoriatic Arthritis management A recently published study, Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers , examines how patients with Psoriatic Arthritis (PsA) perceive the use of digital biomarkers (dBMs) in managing their condition. With the increasing use of wearables like smartphones and smartwatches, there is growing interest in utilizing these tools to track physiological and behavioral data in everyday life. This study, involving 27 PsA patients across six focus groups, sheds light on the potential benefits and limitations of integrating dBMs into PsA care. Key Insights The study identified three main areas of interest: Opportunities: Patients saw value in using digital biomarkers to track early signs of disease flare-ups and monitor symptoms over time. Disease Activity Mapping: Participants highlighted the importance of using a broad range of data points to reflect the complexity of PsA symptoms. Barriers: Concerns about privacy, data security, and maintaining strong connections with healthcare providers were key considerations for patients. Relevance to iPROLEPSIS The findings align with iPROLEPSIS’s goal of integrating patient-centered digital health tools into chronic disease management. This study offers important guidance on ensuring digital health innovations address real-world patient needs while maintaining trust and usability. e004699.full .pdf Download PDF • 1.55MB 1/1 PREVIOUS NEXT

< BACK Insights from iPROLEPSIS 4th Plenary meeting Jul 3, 2024 iPROLEPSIS Plenary Meeting 2024 Recap The 4th iPROLEPSIS plenary meeting took place on 1-2 July 2024 in Munich, Germany, drawing partners from across Europe. The focus was on discussing progress updates and planning future actions towards developing a novel personalised digital care ecosystem for people with Psoriatic Arthritis (PsA). Agenda included: WP overviews, updates and planning next steps General Assembly & External Advisory Board sessions Workshop on : - IDBV (Inflammation digital biomarkers validation study) study: Overview of outcomes, data collection decisions, next steps; - PPIDC (Prevention of PsA inflammation through digital care: an intervention study) study: Objectives, cohort characteristics, study design. WP3 research activities and upcoming deliverables; - iPROLEPSIS ecosystem co-creation, usage scenarios identification, requirements definition; - Serious games co-creation: Introduction to iPROLEPSIS Games app, demonstrations, interactive feedback session. Special Acknowledgment: Gratitude to our patient partners who joined the Serious Games co-creation workshop online and provided valuable insights, ensuring our solutions are truly patient-centric. 1/10 PREVIOUS NEXT

< BACK European Researchers' Night Sep 30, 2024 Engaging Communities through Science Bárbara Ramalho, Hugo Escobar, and Marta Vicente from FMH/IST-ULisboa presented the iPROLEPSIS Games and the iPROLEPSIS project at the European Researchers' Night in Oeiras, Portugal. This event, part of the "Science for Everyone (SCIEVER) – Inclusion and Sustainability" initiative, aimed to engage the public with scientific advancements. Researchers from various fields participated, sharing their work through interactive presentations, live demonstrations, and diverse activities, fostering a stronger connection between science and the community. The event unerlined the importance of making scientific research accessible to all. 1/4 PREVIOUS NEXT

iProlepsis project for psoriatic arthritis uses multi-source data analysis for guiding to a novel personalised digital care ecosystem and maximizes the impact. iPROLEPSIS project vision and impact maximisation Health-to-PsA transition through multi-source data analysis guiding to a novel personalised digital care ecosystem and impact maximisation through openness, visibility, networking and reuse of outcomes. Project vision Data analysis, iPROLEPSIS project goals, IoT technologies and mobile application. About Psoriatic Arthritis Psoriatic Arthritis (PsA) is a chronic, inflammatory disease, affecting the peripheral and axial skeleton, with a severe impact on patients’ quality-of-life. It is estimated that 1-2% of the general population has PsA, i.e., 5 to 10 million people in EU are affected . PsA is associated with psoriasis (PsO) and up to 30% of people living with PsO, i.e., at least 100 million people worldwide (WHO), are expected to develop PsA. The goal The goal of iPROLEPSIS is to propose a novel ecosystem that involves Real Worl Data (RWD) collection mechanisms and a powerful decision support system to provide new knowledge for the key actionable factors that affect the health-to-PsA transition, adopting a multiscale/ multifactorial approach, so, with the use of xAI-based models, to offer an efficient, effective, and clinically validated personalised digital care ecosystem for PsA patients. Technologies IoT sensing technologies and a mobile application will be at the heart of the RWD collection procedure, while retrospective and prospective multi-source data will be collected from the clinical partners’ databases, combined with open access ones. Through the analysis and visualisation of these data using AI predictive models and an intuitive visual analytics tool, respectively, the iPROLEPSIS will be able to propose personalized treatments (i.e., diet, physical activity, stress/fatigue/pain management), assisting doctors, caregivers, and hospitals towards the optimal management of PsA. Finally, through xAI techniques, iPROLEPSIS aims to facilitate hospitals and policy makers in gaining new insights towards better clinical practices, thus shaping future PsA treatment policies. Impact maximisation To ensure the successful implementation of the pathways towards impact in long-term, the project consortium aims at making iPROLEPSIS a reference for the fight against PsA by: 01 Creating an active iPROLEPSIS community of stakeholders. 02 Informing key stakeholders about results and their clinical innovation potential. 03 Making the outputs widely available for research and business purposes in the long term. 04 Increasing people with/at risk of PsA engagement for addressing their issues and concerns in order to increase their awareness and to build trust into new technology. 05 Reaching similar/relevant R&I projects for promoting networking and joint activities. 06 Establishing a forum/community for HCPs and authorities to develop new guidelines and standards. 07 Identifying exploitation mechanisms and activities, assessing the commercialization and applicability of the concepts and ideas. PROJECT OBJECTIVES

< BACK iPROLEPSIS Newsletter No. 6 Oct 9, 2024 Latest News from iPROLEPSIS Welcome to the 6th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_October 2024_ Issue No. 6 .pdf Download PDF • 4.41MB 1/1 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search Quizzes What is psoriatic arthritis? Take a Quiz What are the symptoms of psoriatic arthritis? Take a Quiz How is psoriatic arthritis treated? Drug treatments Take a Quiz How is psoriatic arthritis treated? Self-care and lifestyle Take a Quiz How will psoriatic arthritis affect me? Sleep and Fatigue Take a Quiz How will psoriatic arthritis affect me? Relationships and Family Planning Take a Quiz What causes psoriatic arthritis? Take a Quiz How is psoriatic arthritis diagnosed? Take a Quiz How is psoriatic arthritis treated? Non-pharmacological treatments Take a Quiz How will psoriatic arthritis affect me? Work Take a Quiz How will psoriatic arthritis affect me? Emotional wellbeing Take a Quiz

< BACK iPROLEPSIS at Healthcare & Medical Equipment Korea 2026 Apr 1, 2026 Presenting iPROLEPSIS at Korea’s leading medical technology exhibition Healthcare & Medical Equipment Korea 2026 (KIMES 2026) took place in Seoul, South Korea, from 19 to 22 March 2026. As Korea’s largest specialised exhibition for medical devices and hospital facilities, the event showcased developments in areas such as smart healthcare, AI, robotic medicine, rehabilitation, and medical information systems. iPROLEPSIS was represented at the event by project partner PLUX. The project was presented to an international audience, helping to raise its visibility in the healthcare technology field. The event also provided valuable networking opportunities and supported exchange around biosignal wearables and related digital health solutions. _09A1849.jpg 1.jpg _09A1849.jpg 1/2 PREVIOUS NEXT

< BACK iPROLEPSIS presented at the European OHDSI Symposium 2026 Apr 23, 2026 A poster presented in Rotterdam highlighted cross-country harmonization of psoriatic arthritis cohorts into the OMOP Common Data Model At the European OHDSI Symposium 2026 in Rotterdam, project partner AINIGMA presented a poster entitled Cross-Country Harmonization of Psoriatic Arthritis Cohorts: A Real-World Data Study in the context of the iPROLEPSIS project. Psoriatic arthritis affects 1–2% of the population and shows substantial heterogeneity in symptoms, progression, and treatment response. Real-world evidence is essential to understand long-term outcomes, sex differences, and disease trajectories that are difficult to capture in clinical trials. To identify key inflammation drivers, the team harmonised two national psoriatic arthritis cohorts – the Portuguese Reuma.pt registry and the Dutch DEPAR cohort – into the OMOP Common Data Model (OMOP CDM). This enabled standardised cross-country and sex-stratified analyses. The poster also presented data quality results for this harmonisation work, showing a 95% overall pass rate, including 99% for plausibility, 88% for conformance, and 90% for completeness. As highlighted in the conclusion of the poster, this work shows the value of harmonising data from different national psoriatic arthritis registries into the OMOP CDM to make standardised real-world analyses across European healthcare systems possible. It also opens up new possibilities for advanced analytics, such as federated studies and AI-driven prediction models, beyond this proof-of-concept analysis, advancing iPROLEPSIS’s goal of personalised, data-driven care. Poster_Final_Cross-Country Harmonization of Psoriatic Arthritis Cohorts A real-world data .pdf Download PDF • 1.66MB Media.jpg Media (1).jpg Media (2).jpg Media.jpg 1/3 PREVIOUS NEXT

< BACK iPROLEPSIS Plenary meeting Jun 23, 2023 iPROLEPSIS Consortium Partners Meet in Lisbon to Plan Next Steps The iPROLEPSIS consortium partners gathered in Lisbon, Portugal on June 20-21 for the 2nd Plenary meeting to review the progress and achievements of the project's work packages and plan the next steps. Over the course of two days, the consortium partners engaged in three productive workshops, each focusing on key aspects of the iPROLEPSIS project: Data Collection and Digital Biomarkers: The first workshop delved into the vital task of data collection and the development of digital biomarkers. Attendees discussed the identification of sensor and user data to be collected, including accelerometer/gyroscope data. Additionally, they explored algorithms for identifying inflammation drivers and defined user profiles to enhance personalized healthcare. System Architecture and Cloud Back-end: The second workshop centered around system architecture. The consortium partners discussed the key components of the system, including the orchestrator, and addressed critical aspects such as data management infrastructure and monitoring of app performance issues. miPROLEPSIS App and Serious Games: The third workshop involved a dynamic co-creation session, bringing together clinicians, patients, researchers, and developers. Focusing on the miPROLEPSIS app and serious games, participants explored various areas such as system architecture, key components, data management infrastructure, and app performance monitoring. The adoption of the "Crazy 8s" technique allowed for the rapid generation of a diverse range of ideas. During the third workshop patient representatives joined the session. Their valuable input and perspectives are crucial for understanding the specific needs and requirements of those who will benefit from our iPROLEPSIS project. By actively involving patient representatives, we can ensure that our solutions are truly patient-centric and tailored to their experiences and challenges. The iPROLEPSIS consortium is excited about the progress made during this meeting and is now equipped with a comprehensive plan for the next steps of the project. 3-1.jpg 3-1.jpg 1/1 PREVIOUS NEXT

< BACK Designing Exergames for Psoriatic Arthritis: The Spy and Zen Forest Paradigms Feb 4, 2026 New iPROLEPSIS publication presents the co-design of exergames to support physical activity and rehabilitation in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . Psoriatic arthritis (PsA) is a rheumatic disease affecting the skin and joints and is commonly associated with stiffness, impaired mobility, and chronic pain. In addition to biological treatments, physiotherapy and exercise are often recommended to improve range of motion and physical function. However, low adherence, high costs, and limited engagement frequently reduce the effectiveness of these interventions. The paper presents the design of two exergames – The Spy and Zen Forest – developed as accessible digital tools to complement traditional rehabilitation approaches. Exergames embed therapeutic movements into game mechanics, supporting motivation and consistency in physical activity. Both games were co-designed with 29 experts , including patients with psoriatic arthritis, clinicians, researchers, and technical stakeholders, to ensure alignment with clinical goals, patient needs, and safe physical engagement. In The Spy , players complete physically engaging missions designed to stimulate dynamic body movement and support coordination, mobility, balance, strength, and flexibility. Zen Forest focuses on slow, calm stretching routines inspired by Pilates and Yoga, promoting flexibility, relaxation, and body awareness. Together, the exergames aim to support personalised activity routines and enable clinicians to monitor progress and recommend tailored interventions. Read the full publication: https://zenodo.org/records/18468928 iPROLEPSIS_Zen and Spy.png iPROLEPSIS_Zen and Spy.png 1/1 PREVIOUS NEXT